Acute Myelogenous Leukemia (AML)

Complete a new search

Drug Name
(Proprietary name/Generic name)
Indications Addressed
Click on indication to see all drugs for that indication
Company
Click a company to see all drugs for that company
Development Status Notes
CMA-676
none / CMA-676
Acute Myelogenous Leukemia (AML)
Leukemia
Wyeth Pharmaceuticals
Philadelphia, PA
Phase II/III acute myelogenous leukemia

 

Mylotarg
Mylotarg / gemtuzumab ozogamicin
Acute Myelogenous Leukemia (AML) Wyeth Pharmaceuticals
Philadelphia, PA
Phase I 18 years and younger

 

Acute Promyeloctic Leukemia (APL)

Complete a new search

Drug Name
(Proprietary name/Generic name)
Indications Addressed
Click on indication to see all drugs for that indication
Company
Click a company to see all drugs for that company
Development Status Notes
Atragen¨
Atragen¨ / tretinoin
Acute Promyeloctic Leukemia (APL)
Kaposi's Sarcoma
Kidney Cancer
Non-Hodgkin's Lymphoma
Prostate Cancer
Antigenics
New York, NY
Phase II

 

Gleevec
Gleevec / imatinib mesylate
Acute Promyeloctic Leukemia (APL)
Glioma
National Cancer Institute
Bethesda, MD
Phase I/II (NCI Trial) pediatric

 

Bone Marrow Transplantation

Complete a new search

Drug Name
(Proprietary name/Generic name)
Indications Addressed
Click on indication to see all drugs for that indication
Company
Click a company to see all drugs for that company
Development Status Notes
BPD-MA
none / BPD-MA
Bone Marrow Transplantation QLT
Vancouver, British Columbia
Phase I purging of bone marrow or peripheral blood

 

Nuvion
Nuvion / SMART anti-CD3
Bone Marrow Transplantation
Graft v. Host Disease
Psoriasis
Transplant Rejection
Protein Design Labs
Fremont, CA
Phase I/II

 

Antibiotic-Resistant Infections

Complete a new search

 

Drug Name
(Proprietary name/Generic name)
Indications Addressed
Click on indication to see all drugs for that indication
Company
Click a company to see all drugs for that company
Development Status Notes
tigecycline
none / tigecycline
Antibiotic-Resistant Infections Wyeth Pharmaceuticals
Philadelphia, PA
Phase III  

 

 

 

Bone Cancer

Complete a new search

Drug Name
(Proprietary name/Generic name)
Indications Addressed
Click on indication to see all drugs for that indication
Company
Click a company to see all drugs for that company
Development Status Notes
osteoprotegerin (OPG)
none / osteoprotegerin (OPG)
Bone Cancer
Osteoporosis
Amgen
Thousand Oaks, CA
Phase I bone metastases

 

 

 

 

 

Brain Cancer

Complete a new search

Drug Name
(Proprietary name/Generic name)
Indications Addressed
Click on indication to see all drugs for that indication
Company
Click a company to see all drugs for that company
Development Status Notes
alanosine
none / alanosine
Brain Cancer
Lung Cancer
Non-Small-Cell Lung Cancer
Triangle Pharmaceuticals
Durham, NC
Phase II NSCL

 

allogenic glioma cancer vaccine
none / allogenic glioma cancer vaccine
Brain Cancer Immune Response
Carlsbad, CA
Phase I

 

Avonex¨
Avonex¨ / interferon beta-1A
Brain Cancer
Multiple Sclerosis
Biogen
Cambridge, MA
Phase III monosymptomatic multiple sclerosis, secondary progressive multiple sclerosis

 

chimeric MAb 14.18
none / chimeric MAb 14.18
Brain Cancer National Cancer Institute
Bethesda, MD
Phase III (NCI Trial)

 

Cotara
Cotara / TNT-tumor necrosis therapy
Anaplastic Astrocytoma
Brain Cancer
Colon Cancer
Malignant Glioblastoma
Peregrine
New York, NY
Phase II

 

DTI 015
none / carmustine (BCNU) for intratumoral injection
Brain Cancer Direct Therapeutics
Menlo Park, CA
Phase I/II recurrent glioblastoma multiforme

 

O-6-benzylguanine
none / O-6-benzylguanine
Brain Cancer
Cancer/Chemotherapy-Related Conditions
Colon Cancer
Multiple Myeloma
Sarcoma
Skin Cancer
Solid Tumors
National Cancer Institute
Bethesda, MD
Phase II (NCI TRIAL)

 

phenylacetate
none / phenylacetate
Brain Cancer National Cancer Institute
Bethesda, MD
Phase II (NCI Trial) brain cancer

 

RSR13
none / RSR13
Brain Cancer
Cardiopulmonary Bypass
Gliobastoma Multiforme
Ischemic Heart Disease
Non-Small-Cell Lung Cancer
Allos Therapeutics
Denver, CO
Phase III

 

rubitecan
none / rubitecan
Brain Cancer
Breast Cancer
Cervical Cancer
Colon Cancer
Head and Neck Cancer
Leukemia
Liver Cancer
Lung Cancer
SuperGen
Dublin, CA
Phase II melanoma

 

squalamine
none / squalamine
Brain Cancer
Lung Cancer
Ovarian Cancer
Prostate Cancer
Solid Tumors
Genaera
Plymouth Meeting, PA
Phase II

 

SU101
none / SU101
Brain Cancer
Prostate Cancer
Pharmacia
Peapack, NJ
Phase II/III

 

suramin
none / suramin
Bladder Cancer
Brain Cancer
Solid Tumors
National Cancer Institute
Bethesda, MD
Phase I/II (NCI Trial)

 

targeted toxins
none / targeted toxins
Brain Cancer IVAX Pharmaceutical
Miami, FL
Phase I/II

 

taxane (IV)
none / taxane (IV)
Brain Cancer
Non-Small-Cell Lung Cancer
Solid Tumors
Bayer, Pharmaceutical Division
West Haven, CT
Phase I

 

Xcytrin
Xcytrin / motexafin gadolinium
Brain Cancer
Gliobastoma Multiforme
Pharmacyclics
Sunnyvale, CA
Phase II/III

 

Xerecept
Xerecept / corticotropin-releasing factor
Brain Cancer Neurobiological Technologies
Richmond, CA
Phase I completed

 

 

 

               

Brain Tumors

Complete a new search

Drug Name
(Proprietary name/Generic name)
Indications Addressed
Click on indication to see all drugs for that indication
Company
Click a company to see all drugs for that company
Development Status Notes
adenoviral p53
none / adenoviral p53
Bladder Cancer
Brain Tumors
Breast Cancer
Liver Cancer
Ovarian Cancer
Prostate Cancer
Introgen Therapeutics
Austin, TX
Phase I

 

buthionine sulfoximine
none / buthionine sulfoximine
Brain Tumors
Cancer/Chemotherapy-Related Conditions
Melanoma
National Cancer Institute
Bethesda, MD
Phase I (NCI Trial) overcome resistance to cancer drugs

 

Cereport
Cereport / RMP-7
Brain Cancer
Brain Tumors
Alkermes
Cambridge, MA
Phase II 6 years- 18 years

 

phenylbutyrate
none / phenylbutyrate
Brain Tumors
Colon Cancer
Solid Tumors
National Cancer Institute
Bethesda, MD
Phase II (NCI Trial) pediatric patients (brain tumors)

 

R115777
none / R115777
Brain Tumors
Solid Tumors
Johnson & Johnson Pharmaceutical Research and Development
Raritan, NJ
Phase III 2 years - 18 years

 

SU5416
none / SU5416
Brain Tumors National Cancer Institute
Bethesda, MD
Phase I (NCI Trial) pediatric patients